Prostate-specific membrane antigen antibody drug conjugates

1. A compound comprising Formula (VIII) or (IX) wherein the compound is an anti-prostate-specific membrane antigen (αPSMA) antibody conjugated to a dolastatin, wherein the conjugation occurs via a non-naturally encoded amino acid in the antibody, wherein Formula (VIII) and (IX) correspond to:

wherein:

A is optional, and when present is lower alkylene, substituted lower alkylene, lower cycloalkylene, substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, alkynylene, lower heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene, or substituted aralkylene;

B is optional, and when present is a linker selected from the group consisting of lower alkylene, substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower heteroalkylene, substituted lower heteroalkylene, —O—, -O-(alkylene or substituted alkylene)-, —S—, -S-(alkylene or substituted alkylene)-, —S(O) k — where k is 1, 2, or 3, —S(O) k (alkylene or substituted alkylene)-, —C(O)—, —C(O)-(alkylene or substituted alkylene)-, —C(S)—, —C(S)-(alkylene or substituted alkylene)-, —N(R′)—, -NR′-(alkylene or substituted alkylene)-, —C(O)N(R′)-, —CON(R′)-(alkylene or substituted alkylene)-, —CSN(R′)—, —CSN(R′)-(alkylene or substituted alkylene)-, —N(R′)CO-(alkylene or substituted alkylene)-, —N(R′)C(O)O—, —S(O)kN(R′)-, —N(R′)C(O)N(R′)-, —N(R′)C(S)N(R′)-, —N(R′)S(O) k N(R′)-, —N(R′)—N═, —C(R′)═N-, -C(R′)═N—N(R′)-, —C(R′)═N-N═, —C(R′) 2 -N═N-, and —C(R′) 2 -N(R′)-N(R′)-, where each R′ is independently H, alkyl, or substituted alkyl;

R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl;

R 1 is H, or an anti-PSMA (αPSMA) antibody;

R 2 is OH, or an anti-PSMA (αPSMA) antibody;

wherein the αPSMA antibody comprises a heavy chain of SEQ ID NO. 9, wherein amino acid 116 of SEQ. ID. NO: 9 is substituted with the non-naturally encoded amino acid; and wherein the αPSMA antibody further comprises a light chain selected from the group consisting of SEQ. ID. NOs: 1, 3-8;

R 3 and R 4 are each independently H, halogen, lower alkyl, or substituted lower alkyl, or R 3 and R 4 or two R 3 groups optionally form a cycloalkyl or a heterocycloalkyl;

Z has the structure of:

R 5 is H, COR 8 , C 1 -C 6 alkyl, or thiazole;

R 8 is OH;

R 6 is OH or H;

Ar is phenyl or pyridine;

R 7 is C 1 -C 6 alkyl or hydrogen;

L is a linker selected from the group consisting of alkylene, -alkylene-C(O)—, -(alkylene-O) n -alkylene-, -(alkylene-O) n -alkylene-C(O)—, -(alkylene-O) n —(CH 2 ) n′ —NHC(O)—(CH 2 ) n″ —C(Me) 2 -S—S—(CH 2 ) n′″ —NHC(O)-(alkylene-O) n″″ ,alkylene-, -(alkylene-O) n -alkylene-W—, -alkylene-C(O)—W—, -(alkylene-O) n -alkylene-U-alkylene-C(O)—, and -(alkylene-O) n -alkylene-U-alkylene-;

W has the structure of:

U has the structure of:

 and

each n, n′, n″, n′″ and n″″ are independently integers greater than or equal to one.

2. The compound of claim 1 , wherein R 1 is H and R 2 is an anti-PSMA (αPSMA) antibody.

3. The compound of claim 1 , wherein R 1 is an anti-PSMA (αPSMA) antibody and R 2 is OH.

4. The compound of claim 1 , wherein the non-naturally encoded amino acid is p-acetyl-(+/−)-phenylalanine.

5. The compound of claim 1 , wherein the anti-PSMA light chain is a light chain of SEQ. ID. NO: 1.